Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry

NCT07291999 | Active Not Recruiting

• 1 other identifier: STEMI-RMC Registry
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 3

Brief Summary

This multicenter registry includes patients with a first ST-segment elevation myocardial infarction (STEMI) who underwent cardiac magnetic resonance (CMR) imaging during the acute phase and follow-up. The registry is designed to identify clinical and CMR-derived predictors of adverse ventricular remodeling and major adverse cardiac events (MACE). CMR provides accurate and reproducible assessment of infarct size, left ventricular function, microvascular obstruction, and tissue characteristics, enabling detailed prognostic modeling.

Conditions

Magnetic Resonance; Ischemic Cardiovascular Disease

Keywords

STEMI; Cardiac magnetic resonance

Outcome Measures

Primary Outcomes (1)

• Incidence of MACE (Major Adverse Cardiac Events)

  The primary endpoint is the occurrence of MACE during follow-up. MACE is defined as a composite of the following events: Cardiac death (death attributable to cardiovascular causes) Heart failure hospitalization (unplanned admission with a primary diagnosis of heart failure) Heart transplantation or durable mechanical circulatory support Appropriate ICD therapy (appropriate shock or anti-tachycardia pacing for ventricular arrhythmia in patients with implantable defibrillators). The occurrence of the first event in the composite will be used for time-to-event analyses. The first event in the composite will be used for time-to-event analyses. Event classification will be determined according to standardized definitions and based on review of available medical records.

  From hospital discharge (or index CMR) to at least 6 months, with extended follow-up planned for as long as 5 years, subject to data availability.

Study Arms (1)

Patients

Patients admitted with a first STEMI treated with primary PCI, evaluated by CMR in the acute phase and follow-up

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of patients admitted with a first ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) and were evaluated by cardiac magnetic resonance (CMR) both in the acute phase and during follow-up. The study is conducted in tertiary academic hospitals with well-established CMR programs, ensuring standardized imaging protocols and high-quality data acquisition. Participating centers include the Hospital Clínic de Barcelona, the Hospital Clínico Universitario de Valencia, and the Hospital Universitari Vall d'Hebron, all located in Spain.

You may qualify if:

• Age ≥ 18 years
• First STEMI evaluated within the first 24 hours of symptom onset
• At least one CMR performed during the acute phase

You may not qualify if:

• Severe renal failure (GFR \< 30 ml/min)
• STEMI \> 24 hours after symptom onset
• Contraindications to CMR (e.g., claustrophobia, hemodynamic instability, non-MR-compatible devices, vascular clips)
• Pregnancy or breastfeeding.

Sponsors & Collaborators

• Hospital Clinic of Barcelona: collaborator
• Fundación para la Investigación del Hospital Clínico de Valencia: lead
• Hospital Vall d'Hebron: collaborator

Study Sites (3)

Hospital Vall d'Hebron de Barcelona

Barcelona, 08035, Spain

Location

Hospital Clínic de Barcelona

Barcelona, 08036, Spain

Location

Hospital Clínico de Valencia

Valencia, 46010, Spain

Location

MeSH Terms

Conditions

ST Elevation Myocardial Infarction

Condition Hierarchy (Ancestors)

Myocardial Infarction; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 25, 2025
• First Posted: December 18, 2025
• Study Start: January 1, 2025
• Primary Completion: September 30, 2025
• Study Completion (Estimated): December 31, 2036
• Last Updated: December 18, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

ES (3)